Navigation Links
Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis
Date:7/31/2008

Clinical Data Presented at American Academy of Dermatology Summer Meeting

PRINCETON, N.J., July 31 /PRNewswire/ -- NeoStrata today announced findings from an ongoing 12-week study that demonstrates benefits of a novel topically applied LCD (coal tar) solution (Psorent(TM)) versus calcipotriol cream (Dovonex(R)) in treatment of moderate plaque psoriasis. Specifically, results of an interim analysis reveal the LCD solution is outperforming calcipotriol cream in achieving improvement of psoriasis symptoms (PASI 75) and is significantly better in reducing redness/irritation at both the 2- and 12-week point. Further, patient satisfaction with the aesthetics and ease of use of the LCD solution is high, with nearly 90% of patients expressing an interest in continuing to use the medication after the study's completion.

The clinical data, from a trial conducted by investigator Alexa Kimball, MD, MPH, Massachusetts General and Brigham and Women's Hospitals, Boston, are on display in a Scientific Poster at the Summer Academy Meeting of the American Academy of Dermatology (AAD), July 31 - August 3 in Chicago, IL.

"While coal tar is widely viewed as a very effective treatment for psoriasis, its historically unappealing aesthetic profile has created problems with patient compliance and reduced overall treatment satisfaction," said Dr. Kimball. "These findings demonstrate the non-prescription LCD treatment is at least as effective as a leading prescription medication. Further, they suggest the aesthetically pleasing formulation of the LCD treatment offers a much-needed alternative for safe, effective, easy-to-use topical drug therapy for mild to moderate psoriasis - a welcome tool in our armamentarium."

The 12-week study is evaluating the safety and efficacy of the new topically applied 15% LCD against calcipotriol cream in treatment of 60 patients with moderate plaque psoriasis. The findings, representing interim results for 48 patients, evaluate categorical and mean changes in PASI (Psoriasis Area Severity Index) Improvement as well as PGA (Physician's Global Assessment) scores and patient self-assessment. Findings include:

-- The LCD solution outperformed the calcipotriol cream in the percent of patients achieving PASI 75 (30%); no patients in the calcipotriol group achieved PASI 75, a statistically significant finding, p<0.05.

-- More patients using LCD solution (61%) achieved PASI 50 than patients using calcipotriol (40%), p>0.10.

-- PGA scores versus baseline improved for both treatment groups over the 12-week study. At week 12, the LCD treatment group improved 45% relative to baseline versus the calcipotriol treatment group at 29%, p=0.054.

-- The LCD solution reduced self-assessed redness/irritation, itch and burning significantly faster than the calcipotriol cream after 2 weeks, p<0.05, and was more effective at reducing redness/irritation at 12 weeks, p<0.05. Both treatments significantly reduced all graded parameters relative to baseline at weeks 4, 8 and 12.

Barbara Green, VP, Technology & Clinical Affairs, NeoStrata, said the study confirms their excitement about the efficacy and aesthetic appeal of Psorent, available from physicians without a prescription. In fact, 86% of patients said they would continue to use Psorent even after the study ends, citing that the dab-on applicator allowed them to apply the medication without touching the solution or their plaques. Patients also liked that the solution dried quickly, allowing them to get dressed soon after applying, and that this formulation reduced concerns of staining or mess.

"We developed Psorent to answer patient needs for a non-prescription topical psoriasis therapy that offers a different experience from traditional coal tar treatment -- a formula with similar or better efficacy to a leading prescription medication, that was quick-drying, had an acceptable scent and was easy to apply," said Ms. Green. "The excellent patient satisfaction revealed in this study validates our success in creating this new-generation topical psoriasis therapy that offers clinical efficacy in an aesthetically pleasing non-prescription formulation."

About NeoStrata

The NeoStrata Company, located in Princeton, NJ, develops and markets advanced therapeutic and cosmetic dermatological products through consumer outlets and physicians' offices in the United States and internationally through physicians' offices, pharmacies and spas. http://www.neostrata.com / http://www.psorent.com


'/>"/>
SOURCE NeoStrata
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , Schweiz, April 27, 2016 /PRNewswire/ ... des Sachs CEO Forums in Zürich gab ... ihres führenden Wirkstoffkandidaten STR001 zur Erhaltung des ... eingesetzt wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie ... und Frankreich angeworben. STR001 wird während der ...
(Date:4/27/2016)... Italy , April 27, 2016 ... linear accelerator (MR-linac) platform will be the focal point ... meeting of the European Society for Radiotherapy & Oncology, ... Elekta,s MR-linac integrates a state-of-the-art radiotherapy system and a ... physician to clearly see the patient,s anatomy in real ...
(Date:4/27/2016)... April 27, 2016 Tie-up with ... initiative to save newborns   Fortis ... & newborns in collaboration with Breast Milk Foundation (BMF), a ... Pasteurized Human Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit ... source for infants and should be available to babies deprived ...
Breaking Medicine Technology:
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... East Los ... dental extractions. Currently, patients can visit Dr. Assili to receive any dental extraction treatment ... offer, and it expires June 30, 2016. With the lower price, patients can more ...
(Date:5/2/2016)... ... May 02, 2016 , ... Zitter Health Insights , ... Satisfaction Award that will recognize specialty pharmacies for their achievements in customer satisfaction. ... Specialty Pharmacy Patient Satisfaction Survey compiled throughout 2016. Results will be published in ...
(Date:5/2/2016)... Fla. (PRWEB) , ... May ... ... medical researchers report that many commonly used prescription medications, including anxiolytics, painkillers, ... To mitigate these risks, Novus Medical Detox Center —a leading Florida-based ...
(Date:5/2/2016)... ... May 02, 2016 , ... TeleMedCo™, a new company developing ... and improve the rapid diagnosis, triage and admission of patients leveraging IBM Watson’s ... mobile experience for the first time at GENBAND’s Perspectives16 conference. , TeleMedCo ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... Atlantic Information ... CMS’s Medicare Part B Payment Model Could Transform the Pharma Landscape .” CMS recently ... on reducing its spend on provider-administered drugs while preserving care provided to beneficiaries. The ...
Breaking Medicine News(10 mins):